Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack

Immunology and Cell Biology

Volumn 80, Issue 2, 2002, Pages 131-137

  Maher, Stephen ^a   Toomey, Deirdre ^a   Condron, Claire ^a   Bouchier Hayes, David ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Activation induced cell death; Caspase; Fas (Apo1 CD95); Fas counterattack phenomenon; Fas ligand (FasL CD95L); Immune privilege; Immune system homeostasis; Inflammation

Indexed keywords

CD28 ANTIGEN; CERAMIDE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2; MEMBRANE PROTEIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOLECULAR WEIGHT; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 0036215202     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2002.01068.x     Document Type: Review

References (76)

1. Tyrosine kinase-dependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes
2. Apoptosis by death factor
3. Induction of apoptosis following antigen presentation by T cells: Anergy and apoptosis are two separate phenomena
4. Fas ligand mediates activation-induced cell death in human T lymphocytes
5. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of Fas/FasL expression and cell death
6. Expression of the Fas ligand in cells of T cell lineage
7. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
8. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model
9. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
10. Expression of the functional soluble form of human Fas ligand in activated lymphocytes
11. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
12. Fas and FasL in the homeostatic regulation of immune responses
13. Fas ligand-induced apoptosis as a mechanism of immune privilege
14. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion?
15. Monochloramine enhances Fas (Apo-1/CD95) -induced apoptosis in Jurkat T cells
16. Human lung carcinomas express Fas ligand
17. Two CD95 (APO-1/Fas) signalling pathways
18. Cytochrome c in the apoptotic and antioxidant cascades
19. Two CD95 signalling pathways
20. Signalling pathways in reactive oxygen species-induced cardiomyocyte apoptosis
21. T cell development: Some cells get all the breaks
22. T-cell antigen receptor genes and T-cell recognition
23. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens
24. Lymphocyte activation and its relationship to peripheral tolerance
25. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness
26. Molecular events in the induction of a nonresponsive state in interleukin-2-producing helper T-lymphocyte clones
27. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
28. Fas/FasL interactions required for programmed cell death after T cell activation
29. Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations
30. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis
31. Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance
32. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis
33. Dendritic cells prevent CD95-mediated T lymphocyte death through costimulatory signals
34. The immune response: Chemical mediators, B- and T-cell biology, and immune disorders
35. Not so Fas Re-evaluating the mechanisms of immune privilege and tumor escape
36. Immune privilege or inflammation? Insights into the Fas ligand enigma
37. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
38. A role for CD95 ligand in preventing graft rejection
39. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice
40. Cutting edge: The tumour counterattack hypothesis revisited. Colon cancer cells do not induce T cell apoptosis via the Fas (Apo-1/CD95) pathway
41. Oncogene expression in autoimmune mice
42. Transgenic expression of FasL on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
43. Fas ligand-transfected myoblasts and islet cell transplantation
44. Expression of human Fas ligand on mouse beta islet cells does not induce insulitis but is insufficient to confer immune privilege for islet grafts
45. Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental uveitis
46. Countering the 'counterattack' hypothesis
47. An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome
48. Soluble Fas ligand expression in the ocular fluids of uveitis patients
49. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis
50. The Fas counterattack: Fas mediated T cell killing by colon cancer cells expressing Fas ligand
51. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
52. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma
53. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
54. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
55. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis
56. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer
57. Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: Indications of apoptotic tumor counterattack
58. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies
59. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis
60. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand
61. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defence
62. HLA-DR-Triggered inhibition of haemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand
63. Differential induction of apoptosis by Fas-Fas lLigand interactions in human monocytes and macrophages
64. Human monocytic cells contain high levels of intracellular Fas ligand
65. + adherent tumour cells
66. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
67. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
68. Gene transfer of Fas ligand induces tumor regression in vivo
69. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
70. Technical comments: Constitutive expression of FasL in thyrocytes
71. Technical comments: Constitutive expression of FasL in thyrocytes
72. CD95 ligand (CD95L) immunohistochemistry: A critical study on 12 antibodies
73. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity
74. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival
75. Regulation of the proinflammatory effects of Fas ligand (CD95L)
76. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex